MovDisordV3, Main, Exploration, bibRecordById, Pascal:08-0487365

Uric acid in Parkinson's disease

Identifieur interne : 002547 ( Main/Exploration ); précédent : 002546; suivant : 002548

Uric acid in Parkinson's disease

Auteurs : Ilana Schlesinger [Israël] ; Naomi Schlesinger [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 2008-09-15.

RBID : ISTEX:1B52768F1AF1D4E52BE36D781E990E3059B4D3CB

Descripteurs français

Pascal (Inist)
- Acide urique, Maladie de Parkinson, Pathologie du système nerveux.

English descriptors

KwdEn :
- Antioxidants (therapeutic use), Humans, Nervous system diseases, Parkinson Disease (blood), Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Uric Acid (blood), Uric Acid (therapeutic use), Uric acid, neuroprotection, urate, uric acid.
MESH :
- chemical , blood : Uric Acid.
- chemical , therapeutic use : Antioxidants, Uric Acid.
- blood : Parkinson Disease.
- drug therapy : Parkinson Disease.
- Humans.

Abstract

Recent studies have provided evidence that uric acid may play a role in the development and progression of Parkinson's disease (PD). Uric acid is a natural antioxidant that may reduce oxidative stress, a mechanism thought to play a role in the pathogenesis of PD. Higher levels of serum urate (SU) may have a neuroprotective effect. High SU levels reduced the risk of developing PD and correlated with slower PD progression. Among PD patients SU levels were lower as compared with controls. The manipulation of SU levels holds promise in the treatment of PD. It is possible that a high purine diet in patients with PD may slow progression of the disease. Milk and meat consumption as well as exercise modify the risk of developing PD possibly through their influence on SU levels. In this article, we review the association between PD and SU levels and its implication on the management of PD. © 2008 Movement Disorder Society

Url:

https://api.istex.fr/document/1B52768F1AF1D4E52BE36D781E990E3059B4D3CB/fulltext/pdf

DOI: 10.1002/mds.22139

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Uric acid in Parkinson's disease</title>
<author><name sortKey="Schlesinger, Ilana" sort="Schlesinger, Ilana" uniqKey="Schlesinger I" first="Ilana" last="Schlesinger">Ilana Schlesinger</name>
</author>
<author><name sortKey="Schlesinger, Naomi" sort="Schlesinger, Naomi" uniqKey="Schlesinger N" first="Naomi" last="Schlesinger">Naomi Schlesinger</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:1B52768F1AF1D4E52BE36D781E990E3059B4D3CB</idno>
<date when="2008" year="2008">2008</date>
<idno type="doi">10.1002/mds.22139</idno>
<idno type="url">https://api.istex.fr/document/1B52768F1AF1D4E52BE36D781E990E3059B4D3CB/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002051</idno>
<idno type="wicri:Area/Istex/Curation">002051</idno>
<idno type="wicri:Area/Istex/Checkpoint">001103</idno>
<idno type="wicri:doubleKey">0885-3185:2008:Schlesinger I:uric:acid:in</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:18618666</idno>
<idno type="wicri:Area/PubMed/Corpus">002155</idno>
<idno type="wicri:Area/PubMed/Curation">002155</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002004</idno>
<idno type="wicri:Area/Ncbi/Merge">002208</idno>
<idno type="wicri:Area/Ncbi/Curation">002208</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002208</idno>
<idno type="wicri:Area/Main/Merge">003125</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:08-0487365</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001122</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001B97</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001028</idno>
<idno type="wicri:doubleKey">0885-3185:2008:Schlesinger I:uric:acid:in</idno>
<idno type="wicri:Area/Main/Merge">003636</idno>
<idno type="wicri:Area/Main/Curation">002547</idno>
<idno type="wicri:Area/Main/Exploration">002547</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Uric acid in Parkinson's disease</title>
<author><name sortKey="Schlesinger, Ilana" sort="Schlesinger, Ilana" uniqKey="Schlesinger I" first="Ilana" last="Schlesinger">Ilana Schlesinger</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Neurology, Head, Movement Disorders Clinic, Rambam Health Care Campus, Haifa</wicri:regionArea>
<wicri:noRegion>Haifa</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schlesinger, Naomi" sort="Schlesinger, Naomi" uniqKey="Schlesinger N" first="Naomi" last="Schlesinger">Naomi Schlesinger</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Rheumatology, University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School, New Brunswick, New Jersey</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2008-09-15">2008-09-15</date>
<biblScope unit="vol">23</biblScope>
<biblScope unit="issue">12</biblScope>
<biblScope unit="page" from="1653">1653</biblScope>
<biblScope unit="page" to="1657">1657</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">1B52768F1AF1D4E52BE36D781E990E3059B4D3CB</idno>
<idno type="DOI">10.1002/mds.22139</idno>
<idno type="ArticleID">MDS22139</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antioxidants (therapeutic use)</term>
<term>Humans</term>
<term>Nervous system diseases</term>
<term>Parkinson Disease (blood)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Uric Acid (blood)</term>
<term>Uric Acid (therapeutic use)</term>
<term>Uric acid</term>
<term>neuroprotection</term>
<term>urate</term>
<term>uric acid</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Uric Acid</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antioxidants</term>
<term>Uric Acid</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Acide urique</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Recent studies have provided evidence that uric acid may play a role in the development and progression of Parkinson's disease (PD). Uric acid is a natural antioxidant that may reduce oxidative stress, a mechanism thought to play a role in the pathogenesis of PD. Higher levels of serum urate (SU) may have a neuroprotective effect. High SU levels reduced the risk of developing PD and correlated with slower PD progression. Among PD patients SU levels were lower as compared with controls. The manipulation of SU levels holds promise in the treatment of PD. It is possible that a high purine diet in patients with PD may slow progression of the disease. Milk and meat consumption as well as exercise modify the risk of developing PD possibly through their influence on SU levels. In this article, we review the association between PD and SU levels and its implication on the management of PD. © 2008 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Israël</li>
<li>États-Unis</li>
</country>
<region><li>New Jersey</li>
</region>
</list>
<tree><country name="Israël"><noRegion><name sortKey="Schlesinger, Ilana" sort="Schlesinger, Ilana" uniqKey="Schlesinger I" first="Ilana" last="Schlesinger">Ilana Schlesinger</name>
</noRegion>
</country>
<country name="États-Unis"><region name="New Jersey"><name sortKey="Schlesinger, Naomi" sort="Schlesinger, Naomi" uniqKey="Schlesinger N" first="Naomi" last="Schlesinger">Naomi Schlesinger</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002547 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002547 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:1B52768F1AF1D4E52BE36D781E990E3059B4D3CB
   |texte=   Uric acid in Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Uric acid in Parkinson's disease

Uric acid in Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.